Hemophilia Market Analysis Report By Type, By Treatment, By Therapy, By Region And Segment Forecasts From 2020 To 2027

Industry Insights

The global hemophilia market size was accounted for USD 11.8 billion in 2019. It is also estimated to witness a 5.5% CAGR over the forecasted period, 2020 to 2027. An increase in the R&D spending for the identification of therapeutic agents is projected to drive market growth across the globe.

Several key players have started investing hugely to carry out R&D activities owing to the limited therapeutic options available for the treatment. Moreover, an increasing number of awareness campaigns and initiative plans undertaken by governing authorities for early screening of neonates are anticipated to trigger the adoption of hemophilia diagnostic tools.

The data published by the World Federation of Hemophilia (WFH) stated that men are mostly affected by hemophilia and around 1 from 5,000 neonates suffered from type A, which is a genetic disorder that may result in excessive bleeding and is assumed to have affected more than 400,000 people across the world in 2018.

Type Insights

The global hemophilia market can be classified into type A, type B, type C, and others based on the type. This classification is majorly based on coagulation factor deficiency in patients. Among these, type A is most commonly seen and is recorded to be around four times prevalent than type B.

In 2019, a report published by WebMD LLC stated that type A prevalence across various countries ranges from 5.4 to 14.5 cases in 100,000 males. Also, the patients suffering from severe type hemophilia have major bleeding manifestations. Further, the available products are majorly used for the treatment of type A.

Type B is expected to register the highest growth over the forecasted years, 2020 to 2027. This can be associated with the presence of powerful pipeline products. This type accounts for around 20.o% of the global hemophilia cases and 50% of them have 1% or more factor IX levels.

Treatment Insights

The market across the globe can be segmented into on-demand and prophylaxis based on the treatment type. In 2019, the on-demand treatment segment accounted for the largest share across the global market. The prophylaxis segment is expected to register the highest CAGR from 2020 to 2027.

The prophylaxis treatment is an infusion of clotting factors concentrates that can be used for patients suffering from hemophilia. It is the most trusted treatment that is being accepted worldwide. Its salient features like reduction in the productivity loss that can guarantee good life outcomes are anticipated to trigger market growth in the upcoming years.

Therapy Insights

The global hemophilia market can be segmented into ITI (immune tolerance induction), gene, and replacement therapies based on therapy type. The segment of replacement therapy accounted for the largest market share across the global market in 2019. It is also expected to register the highest CAGR from 2020 to 2027. The surging usage of this therapy in replacing the misplaced clotting factor is expected to contribute majorly towards the growth of this segment.

The segment of gene therapy is also projected to emerge as a prime factor for the identification of defective bases of DNA and for restoring the functional DNAs. For example, potential therapy named AMT-060 is being developed by UniQure for type B treatment.

Regional Insights

North America accounted for the highest share of around 44.4% across the global market in 2019. Shifting inclination towards the prophylaxis medical treatment prevailing among individuals residing across this region is expected to contribute majorly towards the market growth.

The Asia Pacific is projected to register the highest CAGR over the forecasted years, 2020 to 2027. An increase in per capita usage of therapies for catering to factors VIII & IX deficiencies is expected to contribute majorly towards market growth across this region. Moreover, the increasing popularity of these products across countries like India, Malaysia, Japan, and Indonesia is projected to trigger market growth.

COVID-19 Impact Insights

The hemophilia market has been positively impacted due to the ongoing COVID-19 pandemic. The need for the development of early diagnostic tools with the help of DNA bases is gaining traction for fighting against the novel virus. Further, as patients suffering from other diseases such as hemophilia are more prone to get adversely affected by the virus attacks, the need for the development of protective products and medicines is being foreseen by the key players. Moreover, governing bodies across several countries have increased their budget for the healthcare and pharma sector which is expected to trigger the market growth for hemophilia products over the post-pandemic period.

Hemophilia Market Share Insights

The key players operating in the global market are CSL Behring, Bayer AG, Pfizer, Inc., Shire (Baxalta), Novo Nordisk A/S., Octapharma AG, Genzyme Corporation, and Spark Therapeutics, Inc. Continuous innovation and product development is undertaken by these players to gain a cutting edge over other competitive players.

Strategies such as acquisitions, mergers, and regional expansions are also being carried out by these players to widen their geographical reach. For example, Sanofi had bought Bioverativ in 2018 at USD 11.6 Billion for strengthening the market presence across the portfolio of rare diseases.

Report Scope

Segments Covered in the Report

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends from 2016 to 2027 in each of the sub-segments. For this study, Million Insights has segmented the global hemophilia market based on product, treatment, therapy, and region:

• Type Outlook (Revenue, USD Million, 2016 - 2027)
    • Hemophilia A
    • Hemophilia B
    • Hemophilia C
    • Others

• Treatment Outlook (Revenue, USD Million, 2016 - 2027)
    • On-demand
    • Prophylaxis

• Therapy Outlook (Revenue, USD Million, 2016 - 2027)
    • Replacement therapy
    • ITI therapy
    • Gene therapy

• Regional Outlook (Revenue, USD Million, 2016 - 2027)
    • North America
        • The U.S.
        • Canada
    • Europe
        • Germany
        • France
        • The U.K.
        • Italy
        • Spain
    • The Asia Pacific
        • Japan
        • China
        • India
        • South Korea
        • Australia
    • Latin America
        • Brazil
        • Mexico
        • Argentina
        • Colombia
    • Middle East & Africa
        • South Africa
        • Saudi Arabia
        • UAE